Articles Related to leukemia

Acute lymphoblastic leukemia (ALL) is considered as the most common pediatric malignancy with 80% of frequency in children between 1 and 10 years old. With the evolution of science, improved diagnosis and adapted treatment, all survival rates increased to a possibility of 80%. Philadelphia chromosome like acute lymphoblastic leukemia (Ph-Like ALL) is a recent genetic discovery characterized by a gene expression profile and high frequency of IKZF1 gene alteration similar to that of BCR-ABL1 positive ALL with a poor outcome.

View complete article: PDF  |  Full-text

Dasatinib is an orally bioavailable second generation TKI, more potent than imatinib. Bone marrow aplasia or hypoplasia secondary to TKI therapy is an uncommon adverse event. We report here the first case of chronic myeloid leukemia in chronic phase shortly treated with dasatinib that developed a prolonged bone marrow hypoplasia with concomitant response on the hematological disease with gradual improvement of the cytogenetic and molecular response after dasatinib discontinuation, without use of any other TKI therapy.

View complete article: PDF  |  Full-text

Treatment of acute myeloid leukemia is a challenge because of the adverse drug events associated with therapy and the heterogeneous nature of the subtypes. Research on improving overall survival of patients based on different regimens, reduction of adverse dug events, clinical characteristics and the type of acute myeloid leukemia is critical.

View complete article: PDF  |  Full-text

A 51 year old female was referred to our dermatology clinic for a rapidly growing lump on head of 6 weeks duration. On examination we observed a 15 cm diameter erythematous crusted tumor on the forehead with significant bilateral cervical lymphadenopathy. An excision biopsy of the tumor revealed a malignant high grade diffuse undifferentiated infiltrating neoplasm involving the skin and subcutaneous tissue.

View complete article: PDF  |  Full-text

The purpose of the study was to evaluate the management of patients treated with Imatinib for Chronic Myeloid Leukemia (CML) in the Department of Clinical Hematology of the Yalgado OUEDRAOGO University Hospital in Ouagadougou, Burkina Faso.

View complete article: PDF  |  Full-text

T cell acute lymphocytic leukemia (T-ALL) is an aggressive hematologic malignancy in terms of its pathology and populations. It is important to understand the phenomenon of autofluorescence in living cells because normal and cancer cells can be distinguished by this feature. However, the autofluorescence link to T-ALL is poorly understood.

View complete article: PDF  |  Full-text

The clinical outcomes of chronic myeloid leukemia (CML) have been improved by tyrosine kinase inhibitors (TKIs). However, there is no established consensus for TKI selection in de novo CML. We investigated TKI treatment patterns in a real-world setting. Among 95 chronic-phase CML patients, 44% were initiated treatment with imatinib, 26% with dasatinib, and 30% with nilotinib. Our data suggest that imatinib remains applicable and that dasatinib has a favorable therapeutic effect, although pleural effusion can arise. Nilotinib was the most prevalent TKI as the treatment-associated adverse events were deemed more manageable than those associated with imatinib and dasatinib.

View complete article: PDF  |  Full-text

A sixty-five-years-old male patient with history of non-Hodgkin’s lymphoma of the right orbit and a fifty-years-old female patient with chronic lymphocytic leukemia with peripheral lymphocytosis were treated on TomoTherapy. In the first case, a 1 cm beam was used for planning a delivery of 30.6 Gy in 17 fractions with a sequential boost of 9 Gy in 5 fractions. Tumor involvement of the ipsilateral lens and lacrimal gland in the planning target volume necessitated a compromise between preserving patient’s vision and delivery of tumoricidal dose to the target. In the second case, 30 Gy in 20 fractions delivery was planned with a 2.5 cm beam. The tumor extended anteriorly and this technique allowed sparing more orbital tissue and required a high modulation factor.

View complete article: PDF  |  Full-text

Acute myeloid leukemia (AML) is a heterogeneous disease. Therefore, various parameters are needed to classify this disease into subtypes. The commonly used method for diagnosis and classification is based on FAB criteria using morphology and cytochemical stains. For some of the categories, immunopheno typing is necessary. The aim of present study is to determine the frequency of various sub-types in acute myeloid leukemia using FAB criteria in our Sudanese population. This will aid in the correct diagnosis of acute leukemia and hence proper management of the patients.

View complete article: PDF  |  Full-text

Down syndrome or constitutional trisomy 21 was linked to leukemia for the first time in a case report published in 1930 since then, down syndrome has been recognized as one of the most important leukemia – predisposing syndromes and patients with down syndrome and leukemia have unique clinical features and significant differences in treatment response toxicity profiles compared to patients without down syndrome.

View complete article: PDF  |  Full-text

We report here for the first time the efficacy of pegylated interferon α2a (Peg-Ifn) as a therapy for patients with myelofibrosis and high blast counts. We treated four patients who were in an accelerated phase of myeloproliferative neoplasms or acute panmyelosis with myelofibrosis using only this drug.

View complete article: PDF  |  Full-text

Aeromonas infections in humans are becoming increasingly frequent. They have the potential to infect humans and are associated with a variety of illnesses, such as enterocolitis, septicemia, skin and soft tissue infectious and peritonitis.

View complete article: PDF  |  Full-text

We hypothesized that quantitative tandem mass spectrometry-based proteomics, incorporating rapid microwave and magnetic sample preparation (M2 proteomics), might enable relative protein expression to be correlated to childhood B-precursor acute lymphoblastic leukemia (B-ALL) cytogenetic subtypes, corresponding to low-risk (ETV6-RUNX1) and high-risk (MLL-R) subtypes.

View complete article: PDF  |  Full-text

A patient is present who has chronic lymphocytic leukemia (CLL) and developed a vasculitis involving the skin and large vessels along with immune complex mediated glomerulosclerosis. Both vasculitis and immune complex nephritis are rare manifestations of CLL.

View complete article: PDF  |  Full-text

Different therapeutic regimes like chemotherapy, cytokine based immunotherapy and/or stem cell transplantation are generally be the suggested options for treatment of leukemia. However, the selection of the best therapeutic strategy for an individual patient remains uncertain till now

View complete article: PDF  |  Full-text